MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products and delivery devices for patients with endocrine and orphan lung diseases, will showcase inhaled insulin at the American Diabetes Association’s (ADA) 85th Scientific Sessions from June 20-23 in Chicago.
Dr. Michael J. Haller, Professor and Chief of Pediatric Endocrinology at the University of Florida, will present the results from the randomized period of the INHALE-1 clinical trial during a “Future Ready” symposium. Dr. Haller is the Chair for MannKind’s Phase 3 INHALE-1 study of Afrezza (insulin human) Inhalation Powder in children and adolescents (aged 4-17 years of age).
The presentation/posters planned at ADA’s 85th Scientific Sessions regarding the most recent advances in inhaled insulin treatment include:
Symposium – Future Ready – Breakthrough in Pediatric Type 1 Diabetes Care
Sunday, June 22 – 1:30 to 3:00 p.m. (Central) in Room W 181(A-C)
Dr. Michael J. Haller will present: From Discovery to Treatment – Latest Updates on Inhaled Insulin Treatment
Patient Reported Outcomes with Use of Inhaled Technosphere Insulin (T1) (Board 827)
Saturday, June 21, 2025 – 12:30 to 1:30 p.m. (Central)
Presenter: Dr. Peter Calhoun
Efficacy and Safety of Prandial Technosphere Inhaled Insulin (Afrezza) Compared with Placebo in Adult Individuals with T2DM – Results from a Phase III Clinical Trial from India (Board No. 833)
Saturday, June 21, 2025 – 12:30 to 1:30 p.m. (Central)
Presenter: Dr. K M Prasanna Kumar
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.